IL221504B - Compositions and methods for targeting type 1 interferon producing cells - Google Patents

Compositions and methods for targeting type 1 interferon producing cells

Info

Publication number
IL221504B
IL221504B IL221504A IL22150412A IL221504B IL 221504 B IL221504 B IL 221504B IL 221504 A IL221504 A IL 221504A IL 22150412 A IL22150412 A IL 22150412A IL 221504 B IL221504 B IL 221504B
Authority
IL
Israel
Prior art keywords
compositions
methods
producing cells
targeting type
interferon producing
Prior art date
Application number
IL221504A
Other languages
English (en)
Hebrew (he)
Inventor
Panousis Con
Gino Vairo Luigi
Nash Andrew
Maraskovsky Eugene
Wilson Nick
Busfield Samantha
Original Assignee
Csl Ltd
Panousis Con
Gino Vairo Luigi
Nash Andrew
Maraskovsky Eugene
Wilson Nick
Busfield Samantha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL221504(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/707,297 external-priority patent/US20100209341A1/en
Application filed by Csl Ltd, Panousis Con, Gino Vairo Luigi, Nash Andrew, Maraskovsky Eugene, Wilson Nick, Busfield Samantha filed Critical Csl Ltd
Publication of IL221504B publication Critical patent/IL221504B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL221504A 2010-02-17 2012-08-16 Compositions and methods for targeting type 1 interferon producing cells IL221504B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/707,297 US20100209341A1 (en) 2009-02-18 2010-02-17 Treatment of chronic inflammatory conditions
US37448910P 2010-08-17 2010-08-17
US37449710P 2010-08-17 2010-08-17
PCT/AU2011/000155 WO2011100786A1 (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Publications (1)

Publication Number Publication Date
IL221504B true IL221504B (en) 2019-06-30

Family

ID=44482392

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221504A IL221504B (en) 2010-02-17 2012-08-16 Compositions and methods for targeting type 1 interferon producing cells

Country Status (10)

Country Link
EP (1) EP2536430B1 (enExample)
JP (1) JP6018507B2 (enExample)
KR (1) KR101842907B1 (enExample)
CN (1) CN103002913B (enExample)
AU (1) AU2011217728B2 (enExample)
CA (1) CA2789810C (enExample)
ES (1) ES2618562T3 (enExample)
IL (1) IL221504B (enExample)
NZ (2) NZ610826A (enExample)
WO (1) WO2011100786A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3207941B3 (en) * 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
JP2008162954A (ja) * 2006-12-28 2008-07-17 Kirin Pharma Co Ltd 形質細胞様樹状細胞特異的膜分子に対する抗体を含む治療剤
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
JP2011505386A (ja) * 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
NZ601760A (en) 2013-10-25
AU2011217728A1 (en) 2012-09-06
EP2536430A4 (en) 2013-09-04
ES2618562T3 (es) 2017-06-21
AU2011217728B2 (en) 2013-03-14
KR20130004576A (ko) 2013-01-11
NZ610826A (en) 2015-01-30
JP2013519690A (ja) 2013-05-30
CN103002913A (zh) 2013-03-27
KR101842907B1 (ko) 2018-03-28
WO2011100786A1 (en) 2011-08-25
EP2536430B1 (en) 2016-12-14
CN103002913B (zh) 2015-12-16
CA2789810C (en) 2020-12-01
EP2536430A1 (en) 2012-12-26
CA2789810A1 (en) 2011-08-25
JP6018507B2 (ja) 2016-11-02

Similar Documents

Publication Publication Date Title
IL221396A (en) Preparations for the Delivery of Oligonucleotides to Liver Cells, and Methods for their Production
EP2605799A4 (en) CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS
AP2014007572A0 (en) Collector compositions and methods of using the same
EP2585574A4 (en) AROMA COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
IL232716A0 (en) Oligomeric phosphonates and preparations containing them
SG10201602218VA (en) Novel fuel compositions and methods for making same
ZA201401048B (en) Isobutanol compositions for fuel blending and methods for the production thereof
IL224390B (en) Compositions and methods for targeted thermal modulation
PH12013500698A1 (en) Hair-mending compositions and associated methods
IL229176A0 (en) Preparations of living cells and their uses
ZA201209259B (en) Uses and compositions
SG10201601858PA (en) Methods and compositions that provide detergency
GB201006096D0 (en) Novel compositions and uses thereof
ZA201307124B (en) Immunogenic compositions in particlate form and methods for producing the same
EP2572243A4 (en) POLYMERIZABLE COMPOSITION
PT2793954T (pt) Composições de 18f - fluciclovina em tampões citrato
ZA201404399B (en) Bio-pesticide methods and compositions
GB201113770D0 (en) Novel compositions and uses thereof
GB201013443D0 (en) Compositions and methods for producing dendritic cells
PL2646520T3 (pl) Kompozycja na bazie 1,1,1,4,4,4-heksafluorobut-2-enu i 3,3,4,4,4-pentafluorobut-1-enu
IL222343A0 (en) Compositions comprising allogeneic th1 cells and uses thereof
GB201018650D0 (en) Methods and compositions
IL228519A (en) Preparation of 5,3-dioxohexanoate ester in two stages
ZA201304127B (en) Oral compositions and method for producing thereof
ZA201304126B (en) Oral compositions and method for producing thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed